Controlled release drug delivery systems and methods for treatment of an eye

• US 20050244461A1
• Filed: 04/30/2004
• Published: 11/03/2005
• Est. Priority Date: 04/30/2004
• Status: Abandoned Application

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Nivaggioli, Thierry, Blanda, Wendy
• Application Number:
  US10/836,904
• Publication Number:
  US 20050244461A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

Systems and method are provided for treatment of an eye. The systems generally include controlled release implantable elements including a therapeutic component and a substantially inactive matrix component. The systems include such elements having controlled porosities and/or controlled surface roughness. The elements are typically bioerodible and structured to be implantable into a desired location of an eye to provide delivery of the therapeutic component to the eye. The elements exhibit relatively more controllable, more predictable, drug release rate profile in comparison to substantially identical elements without such controlled porosities and/or surface roughness.

Claims

1. A drug delivery system for controlled drug release into an eye comprising:

an element sized and adapted for placement into an eye, said element including a therapeutic component and a matrix component, the therapeutic component being located in combination with the matrix component, the element having at least one of a controlled porosity and a controlled roughness effective in controlling a release rate of the therapeutic component from the element into an eye in which the element is placed.

2. The system of claim 1 wherein the at least one of a controlled porosity and a controlled roughness is effective in controlling the release rate of the therapeutic component from the element into an eye in which the element is placed for a period of time of less than about 14 days after placement in the eye.

3. The system of claim 1 wherein the at least one of a controlled porosity and a controlled roughness is effective in controlling the release rate of the therapeutic component from the element into an eye in which the element is placed for a period of time of less than about 10 days after placement in the eye.

4. The system of claim 1 wherein the at least one of a controlled porosity and a controlled roughness is effective in controlling the release rate of the therapeutic component from the element into an eye in which the element is placed for a period of time of less than about 7 days after placement in the eye.

5. The system of claim 1 wherein the therapeutic component is distributed substantially uniformly throughout the matrix component.

6. The system of claim 1 wherein the element has a controlled porosity and an increase in porosity of the element is effective in increasing the release rate of the therapeutic component from the element into an eye in which the element is placed.

7. The system of claim 1 wherein the element has a controlled roughness and an increase in roughness of the element is effective in increasing the release rate of the therapeutic component from the element into an eye in which the element is placed.

8. The system of claim 1 wherein the at least one of the controlled porosity and the controlled roughness is effective in releasing between about 1% to about 25% of the therapeutic component from the element within about one day of the element being placed in an eye.

9. The system of claim 1 wherein the at least one of the controlled porosity and the controlled roughness is effective in releasing between about 5% to about 20% of the therapeutic component from the element within about one day of the element being placed in an eye.

10. The system of claim 1 wherein the at least one of the controlled porosity and the controlled roughness is effective in releasing between about 10% to about 15% of the therapeutic component from the element within about one day of the element being placed in an eye.

11. The system of claim 1 wherein the at least one of the controlled porosity and the controlled roughness is effective in releasing between about 1 % to about 25% of the therapeutic component from the element within about 7 days of the element being placed in an eye.

12. The system of claim 1 wherein the at least one of the controlled porosity and the controlled roughness is effective in releasing between about 5% to about 20% of the therapeutic component from the element within about 7 days of the element being placed in an eye.

13. The system of claim 1 wherein the at least one of the controlled porosity and the controlled roughness is effective in releasing between about 10% to about 15% of the therapeutic component from the element within about 7 days of the element being placed in an eye.

14. The system of claim 1 wherein at least a portion of the element is biodegradable.

15. The system of claim 1 wherein the matrix component includes a substantially biodegradable material.

16. The system of claim 1 wherein the therapeutic component is selected from the group consisting of cortisone, dexamethasone, fluocinolone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone, and their derivatives.

17. The system of claim 1 wherein the matrix component comprises a polymeric material.

18. The system of claim 1 wherein the therapeutic component is selected from the group consisting of corticosteroids and mixtures thereof.

19. The system of claim 1 wherein the therapeutic component is dexamethasone.

20. The system of claim 1 wherein the matrix component includes a polymeric material including a polymer selected from the group consisting of poly-lactic acid, poly glycolic acid, copolymers of lactic acid and glycolic acid and mixtures thereof.

21. The system of claim 1 wherein the material component includes a polymeric material selected from the group consisting of copolymers of lactic acid and glycolic acid, and mixtures thereof.

22. A method of treating an eye comprising placing the drug delivery system of claim 1 into an eye.

23. The system of claim 1 wherein the matrix component has a controlled roughness and an increase in roughness of the element is effective in increasing the release rate of the therapeutic component from the element into an eye in which the element is placed.

24. A method of making a drug delivery system for modified drug delivery into an eye comprising:

forming an element sized and adapted for placement into an eye, said element including a therapeutic component and a matrix component, the therapeutic component being located in the matrix component, wherein the forming step is conducted at conditions effective in controlling at least one of a porosity of the matrix component and a roughness of the matrix component, in order to provide a controlled release rate of the therapeutic component from the element into an eye in which the element is placed.

25. The method of claim 24 wherein the therapeutic component is distributed in the matrix component.

26. The system of claim 24 wherein the at least one of the controlled porosity and the controlled roughness is effective in releasing between about 1 % to about 25% of the therapeutic component from the element within about one day of the element being placed in an eye.

27. The system of claim 24 wherein the at least one of the controlled porosity and the controlled roughness is effective in releasing between about 5% to about 20% of the therapeutic component from the element within about one day of the element being placed in an eye.

28. The system of claim 24 wherein the at least one of the controlled porosity and the controlled roughness is effective in releasing between about 1 % to about 25% of the therapeutic component from the element within about 7 days of the element being placed in an eye.

29. The system of claim 24 wherein the at least one of the controlled porosity and the controlled roughness is effective in releasing between about 5% to about 20% of the therapeutic component from the element within about 7 days of the element being placed in an eye.

30. The method of claim 24 wherein the matrix component includes a polymeric material.

31. The method of claim 24 wherein the therapeutic component is selected from the group consisting of cortisone, dexamethasone, fluocinolone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone, and their derivatives.

32. The method of claim 24 wherein the therapeutic component is selected from the group consisting of corticosteroids and mixtures thereof.

33. The method of claim 24 wherein the therapeutic component is dexamethasone.

34. The method of claim 24 wherein the matrix component includes a polymeric material selected from the group consisting of copolymers of lactic acid and glycolic acid, and mixtures thereof.

35. The method of claim 24 wherein said forming step includes extruding a combination of the matrix component and the therapeutic component.